Spike S1 RBD (B.1.351 Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit | 78152

Spike S1 RBD (B.1.351 Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit | 78152 | Gentaur US, UK & Europe Disrtribition

Category: Coronavirus/Assay Kit

Application: This kit is useful for screening inhibitors of ACE2 binding to Spike S1 RBD-B.1.351 (SARS-CoV-2).

Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Receptor Binding Domain (RBD) of Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. It has been widely suggested that active as well as passive immunizations targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 offer promising protection against the viral infection.
A variant strain of SARS-COV-2, identified as B.1.351, was first identified in the fall of 2020 in the Republic of South Africa. This South African variant, also known as 501Y.V2, has many mutations which may lead to higher transmissibility and infectivity. In particular, the B.1.351 variant contains three mutations within the RBD region of the Spike S1 protein: K417N, E484K, and N501Y. Investigating the effect of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.

Description: The Spike S1 RBD-B.1.351 (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the RBD region of the B.1.351 Variant of the SARS-CoV-2 Spike S1 protein.

Product Type: Assay Kit

Shippement Condition: -80°C